Email: cspc@cspc.cn
Media
News Center
May. 04
2023
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS
Apr. 21
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL
Apr. 01
VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Mar. 22
VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
Mar. 13
NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION
Mar. 11
FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
